#United States #Ashland #Missouri #ABK Biomedical #Eye90 microspheres

ABK Biomedical: Pioneering Liver Cancer Treatment with New Facility

On October 2, 2026, ABK Biomedical Inc. celebrated a pivotal moment in its history with the groundbreaking of its new commercial manufacturing facility in Cartwright Business Park, Ashland, Missouri. This strategic initiative is not just a landmark in the expansion of ABK Biomedical but also a significant boost for advanced medical technology jobs in the region.

The event was attended by Missouri Governor Mike Kehoe, along with key partners from various sectors including COR Development, Coil Construction, and the University of Missouri, signifying a collaborative effort towards enhancing healthcare innovations. Governor Kehoe's remarks emphasized the importance of this project, highlighting its potential to create skilled jobs and improve patient care globally.

"This project is a testament to the power of collaboration in driving growth and innovation in Missouri," remarked Governor Kehoe. "We are thrilled to welcome ABK Biomedical to our state as it prepares to manufacture cutting-edge medical technologies that will benefit patients around the world."

At the heart of this venture is the Eye90 microspheres®, a clinical-stage device designed for the innovative treatment of liver cancer. The new facility will focus on the commercial-scale production of these microspheres, contributing immensely to the medical landscape and offering hope especially to liver cancer patients requiring advanced treatment options.

Mike Mangano, President and CEO of ABK Biomedical, expressed his excitement regarding this development, noting the long-standing relationship ABK has maintained with the University of Missouri and the local community. Mangano stated, "Today marks a significant chapter for ABK Biomedical. This facility is crucial for our goal of producing Eye90 microspheres at a commercial level, turning research into viable treatment options for liver cancer patients. Our partnership with local organizations has been instrumental in making this vision a reality."

The facility’s design incorporates advanced manufacturing technology tailored to the specific needs of medical device production. David Coil, President of Coil Construction and a co-founding partner of COR Development, emphasized the synergy that can be achieved when local expertise meets groundbreaking medical innovation: "This milestone illustrates what can happen when dedicated professionals in construction and medical technology come together. We are honored to facilitate ABK Biomedical's important manufacturing requirements."

Construction is scheduled to wrap up in 2027, with the facility expected to commence operations in 2028. The Ashland site will not only serve as ABK Biomedical's hub for production but is anticipated to become a cornerstone of a global supply chain aimed at expanding access to its pioneering liver cancer treatments.

Furthermore, this initiative represents a remarkable commitment to the skilled workforce in mid-Missouri, underlining the state's dedication to fostering high-tech industries. The facility’s groundbreaking signifies not just a new chapter for ABK but also for the community that stands to gain from job creation and innovations in healthcare.

In summary, ABK Biomedical's new facility represents a significant leap forward in the quest for effective liver cancer treatments, showcasing the fruitful collaboration between state and local entities in driving medical advancements. As they march towards their goal of commercial production, the potential impact of this project on patients worldwide is immense, reinforcing the vital role that innovation plays in shaping the future of healthcare.

For more information about ABK Biomedical and its innovative treatments, visit ABK Biomedical.